{"id":"NCT01936844","sponsor":"Virginia Commonwealth University","briefTitle":"Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)","officialTitle":"Interleukin-1 Blockade in Acute Decompensated Heart Failure","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-02","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2013-09-06","resultsPosted":"2016-03-22","lastUpdate":"2016-05-05"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure"],"interventions":[{"type":"DRUG","name":"Anakinra (high dose)","otherNames":[]},{"type":"DRUG","name":"Anakinra (standard dose)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Anakinra (short)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days.","primaryOutcome":{"measure":"C Reactive Protein","timeFrame":"3 days","effectByArm":[{"arm":"Anakinra (Short)","deltaMin":2.09,"sd":null},{"arm":"Placebo","deltaMin":2.93,"sd":null}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":15},"commonTop":["Acute kidney injury","Atrial fibrillation"]}}